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Abstract. The availability of licensed paediatric drugs is lagging behind those for adults,
and there is a lack of safe formulations in suitable doses that children are able and willing to
take. As a consequence, children are commonly treated with off-label or unlicensed drugs. As
off-label and unlicensed drug use are associated with a greater risk for harm than on-label
drug use, a range of global initiatives have been developed to realize Bbetter^ medicines for
children. This review describes the challenges and achievements of the European Union to
realize this goal, with a focus on paediatric drug development and formulation design. In
2007, a European Paediatric Regulation was installed enforcing companies to consider
children in the early development of drugs with a new drug substance, for a new indication or
with a new route of administration. The Regulation, e.g. requires companies to develop a
paediatric investigation plan discussing the proposed clinical trials in children of different
ages and the formulations for future marketing. Since 2013, the pharmaceutical design of any
newly marketed paediatric drug should comply with the BGuideline on the Pharmaceutical
Development of Medicines for Paediatric Use.^ Companies should, e.g. justify the route of
administration, dosage form, formulation characteristics, safety of excipients, dosing
frequency, container closure system, administration device, patient acceptability and user
information. In this review, the guideline’s key aspects are discussed with a focus on novel
formulations such as mini-tablets and orodispersible ﬁlms, excipients with a potential risk for
harm such as azo dyes and adequate user instructions.
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INTRODUCTION
Worldwide, the availability of licensed, paediatric drugs
is lagging behind those for adults, and the younger the child,
the fewer drugs available (1–3). Even if a drug is licensed for
paediatric use, it may not be suitable to administer all of the
necessary (lower) doses, it may not be suitable for adminis-
tering the drug to young children, or they may be poorly
accepted (1). Thus, health care professionals are often left
with no other option than to prescribe drugs outside the
approved conditions for age, indication, dose, dosing fre-
quency and/or duration of use (i.e. off-label use); to
recommend an unapproved modiﬁcation of a drug product
such as crumbling tablets and mixing these with food or drink
(i.e. off-label use) or to compound a drug product in the
pharmacy from a mixture of the drug substance and suitable
excipients (i.e. unlicensed drug use) (4, 5). However, off-label
and unlicensed drug use are normally not supported by the
same level of clinical and pre-clinical evidence as drugs that
are used within their approved label conditions. As a
consequence, off-label and unlicensed drug use may result
in altered efﬁcacy rates and an increased risk for harm and
hospitalization (6).
It is evident that market forces alone have proven to be
insufﬁcient in ensuring the availability of licensed and age-
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appropriate drugs for children of different ages. This review
describes the challenges and achievements within the Euro-
pean Union to improve paediatric drug development and the
drug product (formulation) design.
Better Medicines for Children
In 2007, a European Paediatric Regulation (EC No. 1901/
2006) came into force to realize better medicines for the children
of Europe (7). TheRegulation was based on lessons learned from
earlier incentives by the US government which ultimately
resulted in the 2012 Food and Drug Administration Safety and
Innovation Act (FDASIA) (8). The Regulation has already been
described elsewhere (9–11). In summary, it requires companies to
consider children at an early phase in the development of a drug
containing a new drug substance, intended for use in a new
indication or administered via a new route of administration,
unless a waiver applies. In order to fulﬁl this requirement,
companies are obliged to develop a Paediatric Investigation Plan
(PIP) including proposals for the clinical trials in children of
different ages, the dosing recommendations, the formulations for
each of the target age groups and the timelines for drug
development. The PIP is subject to agreement by the European
Medicines Agency (EMA) Paediatric Committee (PDCO).
When new evidence indicates that the proposals in the agreed
PIP are no longer adequate, companies should seek consent from
the PDCO for a modiﬁcation of the PIP. In order to ensure that
the PIP is not just a plan, but also really followed during paediatric
drug development, companies can only apply for drug approval at
the EMA or any of the European national drug regulatory
authorities when compliance to the PIP has been conﬁrmed.
Acknowledging that information on the pharmaceutical
design of paediatric drugs in relation to patient outcomes was
scarce and fragmented, the Paediatric Regulation has trig-
gered a variety of research opportunities (12, 13). In addition,
several research consortia were established, e.g. European
Paediatric Formulation Initiative (EuPFI), Global Research
In Paediatrics network of excellence (GRIP) and European
Study of Neonatal Excipient Exposure (ESNEE) (14–16).
Furthermore, the EMA set up a European Network of
Paediatric Research (Enpr-EMA) to assist stakeholders in
paediatric clinical studies by bringing together research
networks, investigators and centres with recognized expertise
in this domain (17). Besides research, the Regulation has also
promoted the (further) development and harmonization of
national paediatric formularies such as the British National
Formulary for Children and the Dutch Paediatric Formulary
(18, 19). In due course, these will be supplemented by a
harmonized pan European Paediatric Formulary, which is
currently being developed by the European Directorate for
the Quality of Medicines & HealthCare (EDQM) (20).
Paediatric Drug Development: Dosing Aspects
Human growth is not a linear process. As such, children
are not small adults, and paediatric doses cannot be
calculated (extrapolated) as a standardized fraction of the
dose for adults. Rather, the development and use of
paediatric drugs requires speciﬁc knowledge on the age-
related aspects of the drug’s absorption, distribution, metab-
olism and elimination characteristics, i.e. pharmacokinetics
(PK), as well as its receptor and organ interaction, i.e.
pharmacodynamics (PD) (21). Moreover, it must be realized
that the permeability and solubility of a drug substance in
children may differ from adults, meaning that the Biophar-
maceutical Classiﬁcation System (BCS) must be used with
caution (22, 23). When deciding on suitable dosing, other
aspects which may have an impact on the PKPD of a drug
product in an individual child must be considered as well, e.g.
genetic variability (24, 25), maturity of enzymatic systems
involved in metabolism (26), concomitant drug use and co-
existing diseases (27, 28), hypothermic treatment procedures
(29, 30), obesity (31).
Accurate dosing can only be assured when the pharma-
ceutical design of the drug product includes the recom-
mended dose or allows this dose to be measured correctly,
when the child is able and willing to use the drug product as
intended and when the child’s caregiver is able and willing to
administer the dose correctly and as recommended (32–34).
Moreover, a ﬂexible dosage form is required when minor
changes in age, body weight and/or body surface result in
different dosing recommendations (33).
Paediatric Drug Development: EMA Guidance on Drug
Product Design
Background
The European Paediatric Regulation was supported by an
EMA reﬂection paper on BFormulations of choice for the
paediatric population^ describing the issues to be considered
in the pharmaceutical design of drugs for paediatric use (35).
Being a reﬂection paper, the document was intended to
Bcommunicate the current status of discussions and to invite
comments to the topics addressed, rather than to provide
scientiﬁc, technical or regulatory guidance^ (36). Yet, the
reﬂection paper was nevertheless used as such. Therefore, in
2008, the drafting of an actual guideline was initiated by the
publication of a concept paper (32). In order to enable early
dissemination of guidance on the topics addressed, the concept
paper was supplemented with an annex stipulating the basic
guidance principles (32). The guideline itself was adopted in
2013 together with an overview of the stakeholders’ comments
to the draft versions and the way these had been addressed. As
can be read from these overviews, the guideline may be
supplemented in due time with Question and Answer (Q&As)
documents reﬂecting new scientiﬁc evidence (37, 38).
Scope
Drug users may expect that similar drug products will
have similar quality standards regardless of the trademarks
dispensed. For example, that all tablets with a line suggesting
breaking will actually break into equal fragments, or that all
amoxicillin suspensions are well palatable. Acknowledging a
wide variety in patient expectations, patient-reported prob-
lems and medication errors related to paediatric drug design,
it was decided that the guideline should apply across all the
European drug licensing procedures (centralized,
decentralized, mutual recognition, national) and for any new
application, whereas the principles may also be considered for
the PIPs. Moreover, companies were clearly reminded about
242 Riet-Nales et al.
their legal obligation Bto re-evaluate the usefulness (practical-
ity), quality, safety and efficacy of drug products over time,
and, where appropriate, adapt or improve the design of the
drug product in the interest of the drug users and to maintain a
positive benefit to risk profile^ (33). As the guideline was
adopted 6 years after the Regulation had entered into force, it
must be acknowledged that some earlier PIPs may reﬂect
other views than those presented in the guideline.
In order to avoid repetition of data, the guideline is
limited to those aspects of paediatric drug design that differ
between children and adults or at least require further
justiﬁcation. Thus, the guideline should be used in connection
with all other European regulatory provisions such as the
EMA and BInternational Conference on Harmonisation of
technical requirements for registration of pharmaceuticals for
human use^ (ICH) quality guidelines and the European
Pharmacopoeia (Ph. Eur.). Consequently, the paediatric
guideline does not provide an exhaustive list of all aspects
to be considered in paediatric drug design. In Table I, the
authors have prepared a list of issues that may be considered.
Scientific Content
The scientiﬁc content of the EMA paediatric guideline is
divided in sections relating to the route of administration and
type of dosage form (formulation), excipients in the formu-
lation, dosing frequency, ﬁxed dose and modiﬁed release drug
products, container closure systems, administration and
measuring devices, patient acceptability and the user instruc-
tions in the product information, i.e. in the Summary of
Product Characteristics (SmPC), Package Leaﬂet (PL) and/or
on the product label (33).
The guideline indicates that any drug should be designed to
meet patient needs and consistently deliver the intended product
performance (33). In accordance with the ICH Q8 guideline on
BPharmaceutical development,^ a systematic approach to the
pharmaceutical drug design is envisaged including a deﬁnition of
the drug quality target product proﬁle (QTPP) and identiﬁcation
of the product critical quality attributes (CQAs) (33, 64). It is
evident that a drug may often need to be marketed in a range of
strengths and possibly several types of dosage forms. In
exceptional cases, drug products may include different forms of
the active moiety to enable the manufacture of a speciﬁc type of
dosage form, e.g. the salt form rather than the base to ensure that
the active substance dissolves into a solution (33).
Route of Administration, Dosage Form, Formulation
General Considerations
For generations, it was considered that young children
would best be treated with oral liquid formulations, as these
were easy to swallow and would provide adequate dosing
ﬂexibility (65). However, the use of oral liquids may be
associated with numerous problems, including bad taste,
limited chemical, physical and/or microbial stability, need for
a dosing device, risk of errors when measuring the dose,
sedimentation and inhomogeneous distribution of the drug
substance, emulsion splitting, bulky volumes and portability
issues. Most of these problems may be avoided by conven-
tional oral ﬂexible solid paediatric formulations such as
powders or granules; however, these may be badly accepted.
Therefore, newer oral ﬂexible dosage forms such as mini-
tablets or oro-dispersible ﬁlms may be more appropriate (66).
Novel approaches such as the oral solid dosage pen, where
the dose is adjusted by cutting a tablet-like drug carrier at a
pre-deﬁned height, are expected to introduce further ﬂexibil-
ity and convenience to paediatric dosing approaches (67).
Mini-Tablets
The EMA paediatric guideline states that small tablets
(also referred to as mini-tablets) may be considered as a
measure to improve acceptability and dosing ﬂexibility in
children, as several tablets can be taken as a single dose (33).
However, it does not specify when tablets are to be considered
as small, although a limit up to 5 mm has been proposed in the
draft for public consultation (Fig. 1) (37). The guideline clearly
indicates that, apart from size and shape, the suitability of small
tablets should also be justiﬁed in relation to child health
conditions, disease development and the risks associated with
chewing, choking, aspiration and over- and under-dosing (33).
The acceptability of oral formulations in young children,
e.g. mini-tablets, has already been discussed elsewhere. In
summary, we have found that 4-mm uncoated mini-tablets
can be used successfully in children from 1 year of age (46).
In addition, Klingmann et al. showed that smaller 2-mm mini-
tablets can be used in infants from 6 months of age, whereas
2 mm rapidly dissolving mini-tablets can be used as early as in
the pre-term age (47, 48). These studies actually indicated
that mini-tablets are equally or even better accepted than oral
Table I. Aspects to be Considered in a Holistic Approach to Pharmaceutical Drug Product Design
1. Disease characteristics, e.g. need for incidental, intermittent or chronic drug use and duration of therapy (39); need for different routes of
administration (40); impact of the disease on child cognition and behaviour (41); risk for co-morbidities (42, 43);
2. Variability of children within the target age group, e.g. age (1, 44), weight (30, 44), surface area (45) and body composition (30, 44);
3. Characteristics of the individual child, e.g. ability and willingness to swallow a speciﬁc drug product (46–51), multiple medication use or
polypharmacy (27, 44), disease progression (39, 44);
4. Characteristics of the drug substance, e.g. pharmacokinetics (PK), pharmacodynamics (PD) (44), minimum and maximum dose per target
age group and need for small dosing increments (51); minimum and maximum dosing frequency (41); volume of water necessary to dissolve
and swallow the dose (52), impact of oxygen, vapour and higher temperatures on degradation and risk for drug-drug interactions (26, 27);
5. Characteristics of the drug product, e.g. feasibility of the manufacturing process (45), need for inclusion of certain excipients in speciﬁc types
of dosage forms and the safety of such excipients (44, 53), taste (54, 55), need for dosing and other medical devices (33), need for product
handling (56), risk for medication errors (51, 57);
6. Parents’ beliefs, attitudes, convenience and opinions (58, 59), setting where the drug product will need to be administered (52), culture (60);
7. Patient access, e.g. cost (61), reimbursement (51), regulatory challenges (62, 63).
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syrups. Moreover, Kluk et al. conﬁrmed that mini-tablets can
be used as a ﬂexible dosage form since children from 2 years
of age were able to take 5 to 10 tablets in a fruity jelly on a
spoon (49). Although the co-administration of medicines with
food or drink is a common practice in children, concerns have
been raised on the possible impact of the food or drink upon
direct contact with the drug product. The concerns mainly
relate to the possible effect on physical parameters such as
the particle size or tablet coating or on the release of the
active substance from the drug product, i.e. the drug product
bio-availability (65, 68).
The aforementioned studies on mini-tablets were con-
ducted in three European countries only (Germany, Poland,
Netherlands). Therefore, it cannot yet be excluded that
cultural differences inﬂuenced child acceptability. At the
same time, it must be acknowledged that the age at which a
mini-tablet can be taken may depend on the fact as to
whether it must be swallowed intact, whether it may also be
chewed, the presence of coatings and the time to dispersion
or dissolution. In this respect, it must be reminded that the
guideline clearly indicates that immediate release tablets are
normally intended to be swallowed intact but that they may
also be chewed unless otherwise indicated (33). An overview
of current evidence supporting the use of mini-tablets in
children of different ages is published by Liu et al. (69).
Further evidence may be obtained from studies where the use
of mini-tablets was not explicitly reported (58).
Orodispersible Films
Orodispersible ﬁlms are single- or multiple-layer thin
polymer sheets that are intended to be placed in the mouth
where they usually disperse rapidly before being swallowed.
They are not explicitly discussed in the EMA paediatric
guideline, but their suitability for paediatric drug therapy is
increasingly discussed in the scientiﬁc literature (70, 71). The
main advantages of orodispersible ﬁlms include easy admin-
istration, easy dose measurement, limited risk for spillage, no
risk for choking and the possibility to cut the ﬁlm in different
sizes during product manufacture (dosing ﬂexibility). How-
ever, patient acceptability, product mechanical strength,
product packaging and the risk for medication errors
associated with the use of this dosage form require particular
attention. For example, the ﬁlm colour should not trigger
abuse and aspects such as the product taste, ﬁlm texture and
mouthfeel should remain acceptable following the wetting of
the ﬁlm in the mouth. Moreover, the pH at the product-
mucosal interface should not cause irritation and/or pain.
Other disadvantages of orodispersible ﬁlms include limited
load of the drug substance, higher production costs in
comparison to conventional tablets and capsules and the lack
of a harmonized test methods and regulatory provisions (70).
Excipients
Excipients may serve speciﬁc purposes, e.g. diluent,
preservative, colouring agent, coating. According to the ICH
Q8 guideline, the excipients chosen, their concentration, and
the attributes relevant to their function in the drug product
should be justiﬁed. However, excipients that are commonly
used in drugs for adults may not be equally safe when used in
children, even when used in proportional (lower) concentra-
tions (64). Nevertheless, excipients with a potential cause for
concern may be essential to the development of a speciﬁc
dosage form. Therefore, the EMA paediatric guideline
includes a detailed list of points to consider in the evaluation
of the safety proﬁle of excipients. Justiﬁcation can, e.g. be
based on their inclusion in marketed drug products when
certain criteria are fulﬁlled or any relevant opinion of the
European Food Safety Agency (EFSA). Only in exceptional
cases, additional data such as (juvenile) animal studies,
pharmacokinetic data or clinical studies may be necessary
Fig. 1. Volume and size indication of 250 mg oral powder, 2-mm tablet, several 2-mm
tablets and 4-mm tablet on plastic spoon for infant use
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(33). However, in all cases, it must be realized that the use of
a potentially harmful excipient might be avoided by selecting
another route of administration, other type of dosage form,
etc. (33).
Current Experiences
A 5-years evaluation of the formulations in the PIPs
revealed that many questions had been raised to the excipient
composition (72). Following a detailed analysis, we concluded
that the PDCO evaluation had resulted in little changes to the
company’s proposal. Apparently, companies had been able to
adequately answer the EMA questions (73). Acknowledging
that industry would beneﬁt from readily available and up-to-
date information on the safety of excipients in children, the
EuPFI has established a freely accessible Safety and Toxicity
of Excipients for Paediatrics (STEP) database (53). The
consortium has also contributed to valuable excipient reviews,
e.g. by Walsh et al. (54).
Considering that it is relatively easy to implement
changes in the pharmaceutical design of a paediatric drug
product during the early phases of drug development, it is not
yet clear to which extent a precautionary approach to the
excipient composition should be envisaged in the PIPs. For
example, if the proposed formulation in the PIP would
include wheat starch (which may cause problems in some
children with coeliac disease) or lactose (which may cause
problems in some children with lactose intolerance), would
this formulation be acceptable, or should the company be
asked to replace these excipients with other excipients serving
the same function? And what if the formulation in the PIP
includes excipients which may cause problems in children
with less common deﬁciencies, e.g. hereditary fructose/
galactose intolerance? Some excipients are also known for
their allergic potential in children, e.g. arachidis oil, sesame
oil, soya oil. Again, the question arises whether formulations
with such excipients could be accepted in the PIP. Increased
discussion among regulators, industry and academia will help
realizing a transparent and consistent approach on this
dilemma for future applications.
Azo Dyes
In 2007, McCann et al. (University of Southampton)
concluded that six colours that were common in food for
children were associated with an increased risk for hyperac-
tivity (74). These so-called BSouthampton six^ include
Tartrazine (E102), Quinoline Yellow (E104), Sunset Yellow
FCF (E110), Carmoisine (E122), Ponceau 4R (E124) and
Allura Red (E129) (74). In 2008, the study was evaluated by
the EFSA. They concluded that the study showed signiﬁcant
methodological shortcomings, that it was not possible to
pinpoint which of the investigated substances had been
responsible for which of the observed effects and that there
was insufﬁcient reason to change the daily acceptable intake
of the azo dyes E110, E122, E124 and E129 (75). However,
from 2009, a re-evaluation of the safety of colouring agents,
including the Southampton six, has resulted in a reduction of
the acceptable daily intake of E104, E110 and E124. At the
same time, the use of the Southampton six is progressively
decreasing in food for children on a voluntary basis (76).
The EMA paediatric guideline does not include any
speciﬁc guidance on azo dyes, implying that the general points
to consider apply. However, the 2007 BGuideline on Excipients
in the Dossier for Application for Marketing Authorisation of a
Medicinal Product^ clearly indicates that azo dyes (and other
synthetic colouring agents) should not be used in (new
applications for) paediatric drug products (77). Some stake-
holders consider that the 2007 excipients guideline should be
strictly followed, others that the excipient guideline is overruled
by the newer paediatric guideline and the EFSA opinion, which
do not support a strict ban of azo dyes in paediatric drugs (75,
76). Certainly, public acceptance of azo dyes is lower in countries
where voluntary removal of such dyes has occurred in food-
stuffs. Therefore, a harmonized opinion on the acceptability of
azo dyes in paediatric drugs should be envisaged.
A search in the Medicines Information Bank of the
Medicines Evaluation Board in the Netherlands (MEB) on 27
January 2016 revealed that many drugs contain one or several of
the Southampton six: Quinoline Yellow in 110 licensed drug
products for paediatric and/or adult use, Sunset Yellow in 519
products, Carmoisine in 40 products, Ponceau 4R in 97 products,
Allura Red in 27 products (78). A preliminary evaluation of the
lists revealed that some products were actually developed for
use in infants and preschool children. Although further evalu-
ation would be necessary to determine the exact number of drug
products which contain a speciﬁc azo dye per indication and
target age group, the search results support a regulatory
discussion on the acceptability of azo dyes in both newly applied
as well as licensed paediatric drug products.
Excipient Labelling
The need for drug users (health care professionals,
patients, caregivers) to obtain adequate information on the
drug product excipient composition is commonly acknowl-
edged. Therefore, all excipients contained in the drug product
should be listed in the product information. In addition, for
some excipients, the full quantitative information should be
provided to evaluate the excipient burden per single and daily
dose and in case of multiple medication use (79). In 2012, a
multidisciplinary expert group has been established with a
mandate to review the 2003 BGuideline on Excipients in the
Label and Package Leaﬂet of Medicinal Products for Human
Use^ (79). This work has been undertaken to ensure the safe
use of drugs containing excipients with a potential safety
concern, e.g. alcohol. The work is still in progress, but the ﬁrst
recommendations can be found on the EMA website (80).
Paediatric Drug Product Design: Patient Acceptability
Adequate patient acceptability is key to drug efﬁcacy and
safety (33, 50, 54). According to the EMA paediatric guideline,
patient acceptability is determined by the characteristics of the
drug product and the user. Although the term is often
considered equivalent to drug product taste and/or palatability,
the guideline clearly indicates that other aspects may be of
relevance, e.g. product appearance (size, shape, colour, coating,
printing, embossing), package, type of dosing device.
The guideline indicates that, where possible, patient
acceptability should be studied in children as part of the
clinical programme, although it may also be studied through
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other means, e.g. by review of literature references or by
studies in trained adult panels (33). No guidance is given on
the test method and acceptance criteria, implying that any
properly justiﬁed proposal may be accepted (81). The
guideline does not explicitly address in vitro measurements
for taste assessments such as the electronic or e-tongue.
Current evidence indicates that this method can be valuable
to industry when evaluating the effect of taste masking
techniques during product development (82). In due time, a
harmonized opinion on the acceptability testing of paediatric
drugs should be envisaged.
Paediatric Drug Product Design: User Instructions
Any beneﬁt-risk evaluation of a drug product for use in any
patient population is based on the assumption that the beneﬁt is
greatest and the harm is least when the drug is taken as
intended. Therefore, the EMA paediatric guideline stipulates
that the user instructions in the authorised product information
are an integral part of the drug product design (33). Acknowl-
edging that health literacy and information needs may differ
among drug users and that package leaﬂets may get lost, some
European regulatory agencies have a publicly available drug
databasewhere parents can both read the package leaﬂet as well
as the SmPC of a speciﬁc drug product and where a free text
search can be conducted in all the SmPCs and package leaﬂets
that are included in the database (83).
In daily practice, it may not be feasible to use a drug
product as intended, e.g. because of swallowing difﬁculties or
recalcitrance. Therefore, children will beneﬁt from adequate
information on the intended as well as any alternative
administration strategy in the product information (56). Some
of such alternatives have been addressed in the paediatric
guideline, e.g. tablet breaking, administration through a
feeding tube or taking a drug product with food or drink (33).
Breaking
In Europe, break marks may be present to provide
fractions of the full tablet dose or to ease swallowing (84).
The EMA paediatric guideline clearly indicates that the
function of the break mark should be stated in the product
information, i.e. for the administration of lower doses or for
ease of swallowing the full tablet. Where the break mark is
intended for dose reductions, the suitability of the break mark
should be justiﬁed. This implies that the tablets should
comply with the Ph. Eur. test on the Buniformity of mass of
subdivided tablets.^ Acknowledging that scientiﬁc evidence
had indicated that breaking may not be accurate in clinical
practice, the guideline also indicates that break marks for
paediatric dosing may not be accepted in case of potent active
substances with a narrow therapeutic window. The guideline
does not address the use of tablet splitters which have
generally proven to be less accurate than breaking tablets
by hand but rather states that justiﬁcation of the suitability of
the break mark includes the ease of breaking (33, 84).
Feeding Tubes
Children who are premature, seriously ill or who are
otherwise unable to take the necessary calories by mouth may
be nourished through a feeding tube. In such cases, the tubes
are also commonly used to administer oral drugs (85). The
guideline states that where administration through a feeding
tube is highly likely, the product information should indicate
if such administration route is possible and which procedures
are to be adopted. When justifying this route of administra-
tion, aspects to be considered include those related to tube
blockage such as particle size and viscosity or to accurate
dosing such as drug adsorption to the tube material, rinse
volumes and dose recovery after extrusion. In addition, the
risk of accidental aspiration and the potential impact on bio-
availability should be discussed (33).
Administration with Food or Drink
Unless otherwise justiﬁed, drugs should be well
accepted and thus sufﬁciently palatable in children of
different ages when taken on their own or with some
water only (33). However, it is not realistic to expect that
every child will accept a well-developed oral drug
formulation, as the child’s state of mind (behaviour) and
individual preferences may play a role (33). Therefore,
the EMA guideline clearly acknowledges that the lack of
any recommendation on the co-administration or mixing
of drugs with food or drink does not imply that drug users
will avoid this method of administration. Thus, the
guideline requires that companies should undertake the
necessary studies and discuss the joint intake of the drug
product with common foods or drinks in the development
pharmaceutics. In case of relevant interactions, companies
should include a clear warning in the product information
(33).
In-Use Shelf-Lives
The EMA guideline on Bdeclaration of storage
conditions^ describes that companies should study, or other-
wise justify, the shelf-life of drug products after opening of a
multi-dose container. When it cannot be excluded that
opening affects the drug product stability in the licensed
container, an in-use shelf-life should be included in the
product information. When the data indicate that opening
does not have an impact on the drug product stability, no
information on the in-use shelf-life is foreseen.
Some European authorities consider that additional
measures may be necessary to further improve the safe and
correct use of the drug products on their market. For
example, it is known that ADHD patients may use multiple
compartment aids to favour medication management and
ensure adequate drug adherence. Recently, an increase of
tablet cracking was observed for methylphenidate extended
release tablets, possibly because the tablets were stored
outside their licensed container in e.g. a multicompartment
compliance aid. On request of many stakeholders, the
problem was solved by the company on short time by
changing the tablet coating. At the same time, the MEB
agreed that the product information could be supplemented
with information on the period the tablets could be stored
outside their primary container (86).
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Paediatric Regulation: Progress and Future Perspectives
Following 5 years of experience, the EMA concluded that
the Paediatric Regulation was a success, e.g. because drugs were
increasingly being studied in children of younger ages and
because the formulation proposals had prompted discussion with
companies on many issues (72). However, the value of some
paediatric trials is disputed by some stakeholders arguing that
different companies were obliged to conduct similar studies in
small patient populations (62). Moreover, there are uncertainties
on the effectiveness of the Regulation to reduce off-label and
unlicensed paediatric prescription rates as many essential and
common drugs have been licensed before the Regulation entered
into force. For example, Lindell-Osuagwu et al. compared off-
label and unlicensed prescription rates in several paediatric wards
in a Finnish university hospital. They actually found that off-label
use and unlicensed drug use was more prevalent in 2011 than in
2001 (87).Also, on the basis of 117,665 admissions over 1 year in a
French paediatric hospital, Lajoinie et al. concluded that young
children are still commonly treated with unlicensed drugs (88).
All these observations support the need for close
collaboration between regulators, drug developers, hospital
pharmacists and clinical practitioners to evaluate the real
beneﬁt of the Regulation and to propose any adaptations in
the interest of children. In addition, the need to carefully
consider patients as active collaborators rather than subjects
is increasingly acknowledged (89). Acknowledging the limited
number of paediatric use marketing authorisations (PUMAs),
it is commonly agreed that the Regulation may need to be
changed in order to promote paediatric trials in off-patent
drugs, whereas other limitations have been observed as well.
Some adaptations have already been implemented (90).
It may be highly questioned if companies have sufﬁciently
taken their responsibility to improve the design of licensed
paediatric drugs up to the standard outlined in the guideline.
When existing problems prevail, stronger measures may be
considered to ensure that children will have access to age-
appropriate drugs, regardless of the date at which the drug
products were licensed. At the same time, it may be considered
that other populations may have similar needs as children, e.g.
older people (40). Rather than focussing on a gold standard
paediatric drugs, companies may consider the development of
patient centric products that can be used to accommodate
certain patient needs across a wide variety of ages (69).
CONCLUSION
The European Paediatric Regulation has successfully
focussed its attention on the pharmaceutical design of
paediatric drugs. New(er) types of dosage forms, such as
mini-tablets or oro-dispersible ﬁlms, are increasingly being
developed, and information on the safety of excipients is
more readily available. An EMA paediatric reﬂection paper
and guideline have been published to assist industry in the
development of licensed and age-appropriate paediatric drug
products. The guidance goes beyond formulation issues and
also addresses other topics, such as patient acceptability and
drug product usability in clinical practice. The guideline also
stipulates the importance of understandable information for
patients and caregivers in order to increase patient accept-
ability and adequate drug handling. However, further
research in some areas of paediatric drug development is
required in order to assure that paediatric drugs are age-
appropriate and of the required standards, e.g. safety of
excipients, acceptability testing. Progress can be achieved
through closer collaboration of pharmaceutical companies,
regulators, academia, practitioners, patients (children, parents
and other caregivers).
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